| Primary |
| Product Used For Unknown Indication |
28.8% |
| Drug Use For Unknown Indication |
21.3% |
| Epilepsy |
13.6% |
| Convulsion |
7.7% |
| Infantile Spasms |
4.8% |
| Bipolar Disorder |
4.2% |
| Status Epilepticus |
4.1% |
| Drug Exposure During Pregnancy |
2.9% |
| Schizophrenia |
1.5% |
| Lennox-gastaut Syndrome |
1.4% |
| Maternal Exposure Timing Unspecified |
1.4% |
| Partial Seizures |
1.3% |
| Mania |
1.2% |
| Grand Mal Convulsion |
1.1% |
| Myoclonic Epilepsy |
1.0% |
| Depression |
0.9% |
| Schizoaffective Disorder |
0.9% |
| Psychotic Disorder |
0.7% |
| Agitation |
0.7% |
| Affective Disorder |
0.6% |
|
| Completed Suicide |
18.2% |
| Drug Ineffective |
9.2% |
| Poisoning |
8.7% |
| Toxicity To Various Agents |
6.9% |
| Drug Interaction |
4.8% |
| Status Epilepticus |
4.8% |
| Vomiting |
4.8% |
| Convulsion |
4.7% |
| Cerebrovascular Accident |
4.4% |
| Thrombocytopenia |
4.1% |
| Tremor |
4.1% |
| Somnolence |
3.8% |
| Respiratory Arrest |
3.6% |
| Confusional State |
3.0% |
| Speech Disorder Developmental |
3.0% |
| Cardio-respiratory Arrest |
2.7% |
| Pleural Effusion |
2.6% |
| Foetal Exposure During Pregnancy |
2.4% |
| Death |
2.3% |
| Hyperammonaemic Encephalopathy |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
28.3% |
| Epilepsy |
17.7% |
| Drug Use For Unknown Indication |
16.9% |
| Convulsion |
7.0% |
| Bipolar Disorder |
5.7% |
| Status Epilepticus |
3.4% |
| Schizophrenia |
3.0% |
| Psychotic Disorder |
2.3% |
| Depression |
1.9% |
| Grand Mal Convulsion |
1.6% |
| Infantile Spasms |
1.6% |
| Bipolar I Disorder |
1.4% |
| Suicide Attempt |
1.4% |
| Mania |
1.3% |
| Myoclonic Epilepsy |
1.3% |
| Affective Disorder |
1.2% |
| Partial Seizures |
1.2% |
| Agitation |
1.0% |
| Schizoaffective Disorder |
0.9% |
| Insomnia |
0.8% |
|
| Completed Suicide |
21.4% |
| Toxicity To Various Agents |
8.9% |
| Death |
7.6% |
| Thrombocytopenia |
7.0% |
| Malignant Neoplasm Progression |
5.9% |
| Respiratory Arrest |
5.8% |
| Somnolence |
4.4% |
| Vomiting |
4.1% |
| Drug Toxicity |
4.0% |
| Weight Increased |
3.5% |
| Cardio-respiratory Arrest |
3.3% |
| Status Epilepticus |
3.3% |
| White Blood Cell Count Decreased |
3.1% |
| Grand Mal Convulsion |
2.7% |
| Loss Of Consciousness |
2.7% |
| Overdose |
2.7% |
| Tremor |
2.6% |
| Drug Interaction |
2.4% |
| Tachycardia |
2.3% |
| Ventricular Septal Defect |
2.3% |
|
| Concomitant |
| Epilepsy |
18.6% |
| Product Used For Unknown Indication |
16.4% |
| Schizophrenia |
11.2% |
| Drug Use For Unknown Indication |
8.5% |
| Bipolar Disorder |
7.9% |
| Convulsion |
6.6% |
| Depression |
4.6% |
| Status Epilepticus |
3.5% |
| Hypertension |
3.4% |
| Schizoaffective Disorder |
3.3% |
| Affective Disorder |
2.3% |
| Pain |
2.2% |
| Psychotic Disorder |
2.0% |
| Hiv Infection |
1.8% |
| Schizophrenia, Paranoid Type |
1.5% |
| Salivary Hypersecretion |
1.5% |
| Anxiety |
1.2% |
| Sleep Disorder |
1.2% |
| Agitation |
1.2% |
| Partial Seizures |
1.2% |
|
| Vomiting |
12.2% |
| Convulsion |
8.8% |
| Weight Increased |
8.5% |
| Somnolence |
5.3% |
| Thrombocytopenia |
5.3% |
| Urinary Tract Infection |
5.0% |
| Status Epilepticus |
4.9% |
| Rhabdomyolysis |
4.4% |
| Drug Interaction |
4.2% |
| Epilepsy |
4.2% |
| White Blood Cell Count Increased |
4.0% |
| Grand Mal Convulsion |
3.9% |
| Pyrexia |
3.9% |
| Weight Decreased |
3.9% |
| Drug Ineffective |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Pneumonia |
3.6% |
| Rash |
3.6% |
| Platelet Count Decreased |
3.5% |
| Vision Blurred |
3.5% |
|
| Interacting |
| Product Used For Unknown Indication |
13.2% |
| Epilepsy |
11.9% |
| Drug Use For Unknown Indication |
8.5% |
| Convulsion |
7.4% |
| Status Epilepticus |
7.4% |
| Partial Seizures |
6.3% |
| Schizophrenia |
6.1% |
| Bipolar Disorder |
5.0% |
| Complex Partial Seizures |
5.0% |
| Septic Embolus |
4.9% |
| Grand Mal Convulsion |
4.7% |
| Infection |
3.4% |
| Schizophrenia, Paranoid Type |
2.8% |
| Hiv Infection |
2.6% |
| Pneumonia |
2.6% |
| Deep Vein Thrombosis |
2.2% |
| Depression |
1.8% |
| Bacterial Infection |
1.4% |
| Psychotic Disorder |
1.4% |
| Antibiotic Therapy |
1.3% |
|
| Drug Interaction |
32.3% |
| Somnolence |
7.4% |
| International Normalised Ratio Increased |
5.8% |
| Hyperammonaemic Encephalopathy |
5.3% |
| Convulsion |
4.8% |
| Drug Level Decreased |
4.8% |
| Sepsis |
4.8% |
| Toxic Encephalopathy |
4.8% |
| Grand Mal Convulsion |
3.7% |
| Status Epilepticus |
3.7% |
| Tremor |
3.2% |
| Urinary Incontinence |
3.2% |
| Weight Increased |
3.2% |
| Cognitive Disorder |
2.1% |
| Drug Level Below Therapeutic |
2.1% |
| Renal Failure |
2.1% |
| Thrombocytopenia |
2.1% |
| Aphasia |
1.6% |
| Blood Lactic Acid Increased |
1.6% |
| Complex Partial Seizures |
1.6% |
|
